Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19033910 | 0.87 | PDE10A (0.41) | PDE10ASCN10ADOT1LKCNH2POLB | |
| SCHEMBL10284730 | 0.86 | DOT1L (0.42) | PDE10ASCN10ADOT1LKCNH2POLB | |
| SCHEMBL16383235 | 0.86 | DOT1L (0.41) | PDE10ASCN10ADOT1LKCNH2 | |
| SCHEMBL15605852 | 0.86 | PDE10A (0.41) | PDE10ASCN10ADOT1LKCNH2POLB | |
| SCHEMBL16377171 | 0.86 | PDE10A (0.41) | PDE10ASCN10ADOT1LKCNH2POLB | |
| Hydrochloric Acid SCHEMBL16343657 | 0.85 | PDE10A (0.40) | PDE10ASCN10ADOT1LKCNH2POLB | |
| SCHEMBL18659815 | 0.84 | DOT1L (0.40) | PDE10ASCN10ADOT1LAAK1 | |
| SCHEMBL21422820 | 0.84 | DOT1L (0.46) | PDE10ASCN10ADOT1LLMNA | |
| SCHEMBL18325745 | 0.84 | DOT1L (0.46) | PDE10ASCN10ADOT1LLMNA | |
| SCHEMBL23185471 | 0.83 | PDE10A (0.39) | PDE10ASCN10ADOT1LKCNH2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20180127451-A1 | SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-20170313989-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| US-9688714-B2 | Substituted purine compounds | Epizyme, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20160368943-A1 | SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-2646444-B1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | EPIZYME INC (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2012075381-A1 | SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | PDE10A 4017/4885SCN10A 3860/4885DOT1L 1/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | PDE10A 4261/4885SCN10A 4579/4885DOT1L 1/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PDE10A 1424/4885SCN10A 3854/4885DOT1L 6/4885 |
| US-20160368943-A1 | SUBSTITUTED PURINE COMPOUNDS | DIMT1, DOT1L, TPMT | PDE10A 1379/4885SCN10A 4222/4885DOT1L 2/4885 |
| US-20180127451-A1 | SUBSTITUTED PURINE COMPOUNDS | DIMT1, DOT1L, TPMT | PDE10A 1379/4885SCN10A 4222/4885DOT1L 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.